Walleye Capital
CRNX

Walleye Capital’s Crinetics Pharmaceuticals CRNX Stock Holding History

Walleye Capital’s Portfolio CRNX Stock Details CRNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-38,042
Closed -$1.38M – 4801
2026
Q1 		$1.38M Buy
38,042
+33,111
+671% +$1.48M 0.01% 1782
2025
Q4 		$230K Buy
+4,931
New +$220K ﹤0.01% 3470
2025
Q3 		– Sell
-190,373
Closed -$5.48M – 4607
2025
Q2 		$5.48M Buy
190,373
+66,391
+54% +$2.05M 0.02% 824
2025
Q1 		$4.16M Sell
123,982
-17,856
-13% -$667K 0.02% 905
2024
Q4 		$7.25M Sell
141,838
-79,108
-36% -$4.43M 0.02% 839
2024
Q3 		$11.3M Sell
220,946
-94,274
-30% -$4.86M 0.02% 623
2024
Q2 		$14.1M Buy
315,220
+73,858
+31% +$3.41M 0.03% 548
2024
Q1 		$11.3M Sell
241,362
-27,726
-10% -$1.08M 0.02% 761
2023
Q4 		$9.57M Sell
269,088
-165,822
-38% -$5.09M 0.02% 692
2023
Q3 		$12.9M Buy
434,910
+121,312
+39% +$2.5M 0.03% 435
2023
Q2 		$5.65M Sell
313,598
-120,097
-28% -$2.39M 0.02% 656
2023
Q1 		$6.97M Buy
433,695
+28,136
+7% +$521K 0.1% 225
2022
Q4 		$7.42M Buy
405,559
+155,545
+62% +$2.74M 0.14% 182
2022
Q3 		$4.91M Buy
250,014
+95,922
+62% +$1.96M 0.09% 235
2022
Q2 		$2.87M Sell
154,092
-29,451
-16% -$588K 0.08% 274
2022
Q1 		$4.03M Buy
183,543
+95,935
+110% +$1.94M 0.11% 198
2021
Q4 		$2.49M Buy
+87,608
New +$2.16M 0.08% 279
2021
Q1 		– Sell
-12,100
Closed -$171K – 1201
2020
Q4 		$171K Buy
+12,100
New +$169K 0.01% 747

Other funds holding CRNX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JT
Jupiter Topco New York $245B AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Walleye Capital's CRNX Position: Q2 2026 in Review

Walleye Capital sold out of Crinetics Pharmaceuticals (CRNX) in Q2 2026, closing a stake of 38,042 shares — an estimated $1.38M sold.

Walleye Capital first reported a position in CRNX in Q4 2020 and held it in 18 quarters. The position peaked at $14.1M in Q2 2024. 267 funds tracked by Wall St. Rank hold CRNX as of Q2 2026.

  • Walleye Capital reported no remaining Crinetics Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Walleye Capital sold 38,042 Crinetics Pharmaceuticals shares in Q2 2026, an estimated $1.38M.
  • Walleye Capital first reported a position in Crinetics Pharmaceuticals in Q4 2020 and held it in 18 quarters.
  • Walleye Capital's Crinetics Pharmaceuticals position peaked at $14.1M in Q2 2024.
  • 267 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q2 2026.

Based on Walleye Capital's 13F filing for Q2 2026, filed 3 Aug 2026.